WORLD IMMUNOTHERAPY CONGRESS 2019

Part of the FESTIVAL OF BIOLOGICS
DISCOVER • DEVELOP • GET TO MARKET

World Immunotherapy Congress

15th-17th October 2019, Basel Congress Centre, Basel, Switzerland

Advisory board

Ahuva Nissim, Professor, **William Harvey Research Institute, Queen Mary University**
Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich, Roche Pharma Research and Early Development**
Eric Halioua, President and CEO, **PDC*line Pharma**
Lamine Mbow, Senior Vice President and Head, **Glenmark Pharma**

Confirmed Speakers

Abhishek Kashyap, Project Group Leader, Cancer Immunology, Department of Biomedicine, **University Hospital Basel, University of Basel**
Aditya Murthy, Scientist, **Genentech**
Ahuva Nissim, Professor, **William Harvey Research Institute, Queen Mary University**
Alan Smith, Executive Vice President, Technical Operations, **Bellicum**
Alfonso Quintas, Chief Medical Officer, **TCR² Therapeutics**
Ali Mohamed, VP CMC, **Immatics Inc**
Amrik Basran, Chief Scientific Officer, **Avacta**
Andreas Katopodis, CEO, **Anaveon**
Andrei Chapoval, Director, Russian-American Anti-Cancer Centre, **Altai State University**
Anish Suri, Senior Vice President, Chief Scientific Officer, **Cue Biopharma**
Anthony O'Kane, Head of Antibody Discovery, **Fusion Antibodies**
Carla C. Baan, Head of Laboratory, Internal Medicine – Transplantation & Nephrology, **Erasmus MC**
Carmela De Santo, CRUK New Investigator Fellow, **University of Birmingham**
Caroline Hull, PostDoctoral Research Associate, **Kings College London**
Carolyn Edwards, Principal Scientist, **Crescendo Biologics**
Christian Fischer, Staff Scientist, MRS Application Development, **Bruker Biospin**

Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich, Roche Pharma Research and Early Development**
Christiane Niederlaender, Director, **AMBR-Consulting,** Formerly Senior Quality Assessor for Biologics and CAT member, **MHRA**
Christophe Quéva, Chief Scientific Officer, **Oncorus**
Christopher Barnum, Director of Neuroscience, **INmune Bio**
Dario Neri, Professor of Chemistry and Applied Biology, **Swiss Federal Institute of Technology Zurich**
David Maurer, Principal Scientist, **Distributed Bio -** Representing **Charles River**
Dirk Jäger, Managing Director, **NCT Heidelberg**
Elena Costariol, EngD Researcher, **University College London**
Eric Halioua, President and CEO, **PDC*line Pharma**
Eva Dahlen, Senior Director, Business Development, **Alligator Bioscience**
Ezio Bonvini, Chief Scientific Officer, **MacroGenics**
Farshad Guirakhoo, Chief Scientific Officer, **GeoVax**
Frederic Triebel, Chief Scientific Officer, Chief Medical Officer, **Immutep**
Gennaro De Libero, Professor, **University of Basel**
Guillaume Beyrend, Marie Curie Early Stage Researcher, **Leiden University Medical Centre**
Hans S. Keirstead, Chief Executive Officer, **AIVITA Biomedical, Inc.**
Hanspeter Gerber, SVP & CSO, **3T Biosciences**
Heinz Laubli, Attending Physician, Medical Oncology, **University Hospital Basel**
Jeanette Leusen, Associate Professor, Head Immunotherapy group and UMAB, Laboratory of Translational Immunology (LTI), **University Medical Center Utrecht**
Jim Eyles, Principal Scientist, **AstraZeneca**
Jing Zhao, Chief Business Officer, **Refuge Biotechnologies**
Johan Lantto, Project Director, Immuno-Oncology, **Symphogen**
Johannes vom Berg, Group Leader, Institute of Laboratory Animal Science, **University of Zurich**
Kader Thiam, Vice President of Transgenic Technologies, g**enOway**
Karin Hägerbrand, Scientist, Immuno-oncology, **Alligator Bioscience**
Karoline Schjetne, VP Scientific Affairs, **Vaccibody**
Kiyoshi Takayama, Founder and President, **NB Health Laboratory Co**
Lamine Mbow, Senior Vice President and Head, **Glenmark Pharma**
Limin Shang, Director of Pharmacology, **Light Chain Bioscience – A Brand of Novimmune SA**
Linda Klauss, Field Application Specialist, **Gyros Protein Technologies**
Lisa Kinsella, Head Legal Biotechnology, Cell and Gene, **Novartis**
Luke Lee, CEO and Founder, **3T Biosciences**
Maria Fiammetta Romano, Associate Professor of Biochemistry, **University of Naples "Federico II"**
María Gonzalez-Pajuelo, CSO, **FairJourney Biologics**
Markus Zettl, Director of Immuno-Oncology, **Pieris Pharmaceuticals**
Marta Trüb, Postdoctoral Researcher, Cancer Immunology Group, Department of Biomedicine, **University Hospital Basel, University of Basel**
Martine Boks, Scientist, **Merus**
Maryam Shariatzadeh, Post-Doctoral Researcher, Centre for Biological Engineering, **Loughborough University**
Meelis Kadaja, Director of Business Development, **Icosagen**
Meltem Elitas, Associate Professor, **Sabanci University**
Michael Humbert, Co-Founder & Laboratory Director, **NTxBio**
Michael Streit, Executive Director, Clinical Development, Oncology R&D, **GlaxoSmithKline**
Nabila Seddiki, Associate Professor, **INSERM**
Nicolas Poirier, Chief Scientific Officer, **OSE ImmunoTherapeutics**
Nicolò Rigamonti, Project Leader and Biology Lead, **Molecular Partners**
Nina Reschke, Senior Scientist, Immuno-Oncology Research, **Molecular Partners**
Oliver Hill, Vice President, Molecular Biology, **Apogenix**
Otmane Boussif, Global Head Cell & Gene Therapy Technical Development, **Novartis**
Partha Chowdhury, Senior Director, Head of Antibody Discovery, **Sanofi Genzyme**
Paul Cockle, Head of Immunology, **PsiOxus Therapeutics**
Peter Djali, European Director of Sales, **IsoPlexis**
Peter Luo, Founder and CEO, **Adagene**
Philip Beer, Visiting Scientist, **Sanger Institute,** Consultant Genomicist, **NHS**
Rajita Pappu, Senior Scientist, **Genentech**
RJ Tesi, CEO, **INmune Bio**
Robert Thomas, Professor, Manufacturing for Cell and Gene Therapies, Centre for Biological Engineering, **Loughborough University**
Ryan Cawood, CEO, **OXGENE**
Sara Colombetti, Global Head of Oncology Discovery Pharmacology, **Roche Innovation Centre Zurich**
Sijme Zeilemaker, Senior Director Business Development, **Immunicum**
Stephen Beers, Associate Professor, **University of Southampton**
Svetlana Chapoval, Assistant Professor, **University of Maryland**
Sylvain Julien, Chairman and co-founder, **e-Zyvec**
Thomas Hach, Worldwide Brand Medical Director, Neuroscience, **Novartis**
Thomas Valerius, Assistant Professor, Stem Cell Transplantation and Immunotherapy, **University of Kiel**
Tim Fugmann, Senior Scientific Advisor, **Alithea Bio**
Ulrich Rant, CEO, **Dynamic Biosensors**
Veeren Chauhan, Future Targeted Healthcare Manufacturing Research Fellow, **Nottingham University**
Zoe Nilsson, Global Product Marketing Manager, **Sphere Fluidics**

Workshop moderators

Alan Smith, Executive Vice President, Technical Operations, **Bellicum**

Ali Mohamed, VP CMC, **Immatics**

Day 1 – Tuesday 15th October 2019			
08:00	Registration opens		
08:30	Conference doors open		
08:45	Welcome from Terrapinn		
	ROOM SINGAPORE **Opening keynotes** Chaired by: **Michael Streit,** Executive Director, Clinical Development, Oncology R&D, **GlaxoSmithKline** (CONFIRMED)		
09:05	Chair's opening remarks **Michael Streit,** Executive Director, Clinical Development, Oncology R&D, **GlaxoSmithKline**		
09:10	**Leveraging innate and adaptive immunity for immunotherapy of cancer** • Fc-engineering delivers enhanced innate immunity, such as enhanced ADCC • Induction of cancer-specific T- and B-cell responses has also been observed • Evidence of innate/adaptive immunity cross-talk by Fc-engineered antibodies will be discussed **Ezio Bonvini,** Chief Scientific Officer, **MacroGenics** (CONFIRMED)		
09:30	**Bintrafusp alfa (M7824): A next generation immune-oncology agent** • Up-regulation of genes associated with the cytokine TGF-beta has been linked to resistance against PD-1/PD-L1 -targeting monoclonal antibodies • Neutralization of TGF-beta is a promising new approach to overcome primary resistance and sensitize tumours to anti PD-1/PD-L1 therapies • Bintrafusp alfa (formerly known as M7824) is a bifunctional protein designed to simultaneously block the PD-L1 and TGF-beta pathway in the tumour microenvironment • Pre-clinical and preliminary clinical data indicate that by addressing the independent and complementary immunosuppressive functions of PD-L1 and TGF-beta, treatment with Bintrafusp-alfa may lead to superior antitumor activity compared to PD-1/PD-L1 blockade alone **Michael Streit,** Executive Director, Clinical Development, Oncology R&D, **GlaxoSmithKline** (CONFIRMED)		
09:50	**ONCR-177, a novel Micro-RNA attenuated oncolytic HSV virus with combinatorial immune payloads for the treatment of metastatic cancer** • Oncorus is advancing ONCR-177, a microRNA attenuated HSV-1 expressing IL-12, CCL4, FLT3L and antagonist of CTLA4 and PD-1 in the clinic. • Preclinical data supporting ONCR-177 mode of action via selective tumour cell killing and the development of a potent antitumor immune activation will be presented **Christophe Quéva,** Chief Scientific Officer, **Oncorus** (CONFIRMED)		
10:10	Networking break		
11:20	**Plenary roundtable session**		
	TABLE 1 Title TBA **Eric Halioua,** President and CEO, **PDC*line Pharma** (CONFIRMED)	TABLE 2 **From research to clinical practice, how can precision medicine strategies be implemented for patient selection and stratification?** **Tim Fugmann,** Senior Scientific Advisor, **Alithea Bio** (CONFIRMED)	TABLE 3 **Antibody combinations for cancer immunotherapy** **Johan Lantto,** Project Director, Immuno-Oncology, **Symphogen** (CONFIRMED)
	TABLE 4 **Current challenges in developing cell and gene therapy processes** **Otmane Boussif,** Global Head Cell & Gene Therapy Technical Development, **Novartis** (CONFIRMED)	TABLE 5 **Quality regulatory considerations for CAR-T cells and genetically modified cells** **Christiane Niederlaender,** Director, **AMBR-Consulting,** Formerly Senior Quality Assessor for Biologics and CAT member, **MHRA** (CONFIRMED)	TABLE 6 **Biologics, cell and gene – Unique therapies with unique legal requirements** **Lisa Kinsella,** Head Legal Biotechnology, Cell and Gene, **Novartis** (CONFIRMED)

12:35	Networking lunch			
	ROOM SINGAPORE **Immune checkpoint modulation**	**ROOM HELVETIA 3-5** **Cell therapy**	**ROOM HELVETIA 7** **Tumour microenvironment** Chaired by: **RJ Tesi**, CEO, **INmune Bio** (CONFIRMED)	**ROOM RIO** **Technology showcase**
14:10	**Combination of targeted cytokines with immune check-point inhibitors** • Antibody-cytokine fusions • Combination therapy results • Phenotyping of immune infiltrate • Immunodominant tutor-rejection antigens **Dario Neri,** Professor of Chemistry and Applied Biology, **Swiss Federal Institute of Technology Zurich** (CONFIRMED)	**The TRuC-T cell platform -- overcoming CAR-T and TCR limitations** • Advantages of the TRuC Platform – using the full TCR complex without HLA matching • TRuC-T cells' potential to address solid tumors and hematologic malignancies • Phase 1/2 trial design for our lead solid tumor and hematologic malignancy candidates **Alfonso Quintas,** Chief Medical Officer, **TCR² Therapeutics** (CONFIRMED)	**Cancer immunotherapy by manipulation of tumor-associated glycosylation** • Impact of the cancer-associated glycosylation on immune suppression • Enzymatic targeting of cancer-associated glycosylation • Discussion of the sialoglycan/Siglec pathway as new target for cancer immunotherapy • Glycan manipulation for cellular therapies **Heinz Laubli,** Attending Physician, Medical Oncology, **University Hospital Basel** (CONFIRMED)	**14:10 Bispecific binding analysis with the two-color switchSENSE® biosensor** • Simultaneous detection of interactions of bispecific binders with two antigens • Analysis of on- and off-rates • Avidity vs. affinity analysis • Engineering of binding selectivity **Ulrich Rant,** CEO, **Dynamic Biosensors** (CONFIRMED)
14:35	**A soluble LAG-3 protein (eftilagimod alpha) with an anti-PD-1 antibody (pembrolizumab): a new combination in immuno-oncology** • Eftilagimod alpha (LAG-3Ig or "efti"), a powerful APC activator targeting MHC II molecules • Stepping on the accelerator (APC activation by efti) while releasing the brake (pembrolizumab) on the T cells • TACTI-mel phase I trial (24 patients with metastatic melanoma) and TACTI-002 phase II trial (109 patients, metastatic NSCLC first or second line, HNSCC) **Frederic Triebel,** Chief Scientific Officer, Chief Medical Officer, **Immutep** (CONFIRMED)	**Targeting drugs to the arthritic joint using extracellular vesicles enriched with damaged cartilage specific antibody** • Rheumatoid arthritis is the second most common form of arthritis • Although significant progress in treatment has been made, ~40% patients do not respond to treatments and treatments result in increased risk of infection • We utilise antibody that is specific to arthritis cartilage to target extracellular vesical cargo enriched with multiple therapy **Ahuva Nissim,** Professor, **William Harvey Research Institute, Queen Mary University** (CONFIRMED)	**Improving myeloid effector cell recruitment for immunotherapy** • Impact of antibody isotypes • Myeloid immune checkpoint Blockade • Antibody combination therapy **Thomas Valerius,** Assistant Professor, Stem Cell Transplantation and Immunotherapy, **University of Kiel** (CONFIRMED)	**14:30 Computational immuno-engineering therapeutics against challenging targets: GPCR antagonists, broad neutralizers, blood-brain barrier transit, and species cross reactivity** • Learn how to: discovery hits against previously challenging targets including GPCRs, pMHC complexes, and rare epitopes • Discover why: affinity, cross-species coverage, and improved drug-like characteristics is important for an antibody library • Learn how to: generate thousands of human-like hits in the fraction of the time it takes for traditional methods **David Maurer,** Principal Scientist, **Distributed Bio -** Representing **Charles River** (CONFIRMED)
15:00	**Neutralizing CD47 with bispecific antibodies**		**Targeting the tumour microenvironment – Under every stone sleeps a scorpion**	**14:50 Mammalian display antibody discovery for integral membrane proteins** • Novel viral based platform for discovery of antibodies in mammalian cells

	• CD47 is an ubiquitous innate immune checkpoint • Bispecific antibodies allow for guided inhibition of CD47 and Fc-mediated tumour cell killing • CD47 checkpoint blockade with bispecific antibodies relieves immunosuppression in the tumour microenvironment **Limin Shang,** Director of Pharmacology, **Light Chain Bioscience – A Brand of Novimmune SA** (CONFIRMED)	**A synthetic biology approach to immunotherapy: Designing intelligent smart cells to combat cancer** • Combination therapy the future when it comes to treating cancer • Combining cell therapy and checkpoint biology into a single inducible system using CRISPR interference and activation **Jing Zhao,** Chief Business Officer, **Refuge Biotechnologies** (CONFIRMED)	• Resistance mechanisms to antibody effector function are complex • Understanding target expression is key to effective translation • mAb format is critical to activity and is particularly relevant when developing mAb to target the tumour microenvironment **Stephen Beers,** Associate Professor, **University of Southampton** (CONFIRMED)	• Integral membrane proteins are expressed in their native configuration on the cells surface • Optimised discovery libraries for improved hit identification with up to 1e9 diversity **Ryan Cawood,** CEO, **OXGENE** (CONFIRMED)
15:25	Extended Q&A			**15:10 e-Zyvec assembly method : a new modular technology to assemble tailor-made DNA vectors** • Limitations in classical cloning methods • Our technological answer • Example of applications **Sylvain Julien,** Chairman and co-founder, **e-Zyvec** (CONFIRMED)
15:30				
	ROOM SINGAPORE **Immune checkpoint modulation**	**ROOM HELVETIA 3-5** **Cell therapy**	**ROOM HELVETIA 7** **Tumour microenvironment** Chaired by: **RJ Tesi**, CEO, **INmune Bio** (CONFIRMED)	**ROOM RIO** **Technology showcase**
16:30	**Tumour localised activation of the immune system using bispecific anticalin/antibody fusion proteins** **Markus Zettl,** Director of Immuno-Oncology, **Pieris Pharmaceuticals** (CONFIRMED)	**Cell and gene therapy products: Current and future manufacturing processes** • Stem cells cultivation • Gene editing techniques • Regulatory challenges and opportunities • Process changes and comparability strategies **Otmane Boussif,** Global Head Cell & Gene Therapy Technical Development, **Novartis** (CONFIRMED)	**Targeting Protector Cells of the TME to improve efficacy of Immunotherapy** • "Protector cells" of the TME, MDSC, Treg and TAM, promote resistance to immunotherapy • Eliminating MDSC and TAM will improve response to therapy by decreasing immunosuppression and converting cold tumor to hot tumors • Targeting sTNF with INB03 is an effective strategy for eliminating MDSC and TAM and improving NK/DC crosstalk to improve recruitment of TIL • Determination of resistance factors before treatment should allow targeted combination therapy to be effective in selected patients **RJ Tesi**, CEO, **INmune Bio** (CONFIRMED)	**16:30 Cyto-Mine®: Accelerating antibody discovery** • Microfluidic picodroplet technology is helping to revolutionize antibody discovery • Addresses the key needs of reduced costs, higher throughput and greater sensitivity in finding and isolating rare B cells secreting antigen-specific antibodies during antibody discovery • Offering solutions to help transform antibody discovery and the development of novel biotherapeutics **Zoe Nilsson,** Global Product Marketing Manager, **Sphere Fluidics** (CONFIRMED)

16:55	**Fibroblast activation protein (FAP)-targeted 4-1BBL agonist amplified effector functions of intratumoral T cells in human cancer** • Tumor targeted therapies directed against co-stimulatory receptor 4-1BB are attractive therapeutic avenue for cancer patients to boost anti-tumoral T cell responses • Combination treatment with fibroblast activation protein (FAP)-4-1BBL and T cell receptor stimulation significantly enhances T cell activation and effector functions in primary tumor suspensions from lung cancer patients • Co-stimulation with FAP-4-1BBL leads to de novo secretion of interleukin (IL)-13 by intratumoral T cells, which facilitates tumor cell apoptosis **Marta Trüb,** Postdoctoral Researcher, Cancer Immunology Group, Department of Biomedicine, **University Hospital Basel, University of Basel** (CONFIRMED)	**Immune cell polyfunctional subsets - Implication for research, as a potential treatment biomarker and in predicting clinical outcome** • We will present data showing how polyfunctionality measured by IsoPlexis correlates with patient objective response • How this can be used to enhance CAR-T manufacturing and relates to clinical observations in combination therapies **Peter Djali,** European Director of Sales, **IsoPlexis** (CONFIRMED)	**Lowering the threshold for effective anti-tumour immunity** • An immunosuppressive microenvironment antagonizes optimal effector function of cytotoxic lymphocytes • Host germline genetics can inform us about pathways that drive immunosuppression in cancer • Tuning the microenvironment to support inflammatory leukocyte function can shift the immune set-point • Specific example: Targeting the autophagy pathway boosts immune effector function for therapeutic benefit **Aditya Murthy,** Scientist, **Genentech** (CONFIRMED)	**16:50 HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species** **Meelis Kadaja,** Director of Business Development, **Icosagen** (CONFIRMED)
17:20	**Generation & proof-of-concept of DARPin®-based T-cell engagers** • Development of a DARPin®-based T-cell engager platform • Functionality of T cell redirecting DARPins® • Opportunities of DARPin®-based T-cell engagers to address current limitations in the clinic **Nina Reschke,** Senior Scientist, Immuno-Oncology Research, **Molecular Partners** (CONFIRMED)	**Drug resistant immunotherapy: Strategic combinations of chemotherapy, γδ T cells, and immune modulation as adjuvant therapy for primary malignancy** • Strategic timing of chemotherapy and immunotherapy leverage the innate response to chemotherapy-induced expression of stress-associated antigens and depletion of regulatory T cells in the local microenvironment • Genetic modification of γδ T cells for chemotherapy resistance enables cytotoxic lymphocyte function in otherwise lymphodepleting concentrations of chemotherapy at a time when the tumor is maximally stressed • Immunomodulation strategies such as checkpoint inhibition can boost	**Dynamic cell culture array and pattern recognition algorithms to understand role of macrophages in tumour microenvironment** • Contribution of macrophages into tumor invasiveness • Image processing and machine learning algorithms to interrogate tumor microenvironment • Mimicking complex tumor microenvironment with 2D and 3D microfabricated cell-culture arrays **Meltem Elitas,** Associate Professor, **Sabanci University** (CONFIRMED)	**17:10 The journey to "the" antibody: Tailoring for success** • To maximize the possibility to select "the" antibody, at FJB we have taken antibody discovery to an unprecedent level by creating a versatile toolbox that allows the selection by phage display of antibody fragments of different species from large naïve and immune repertoires. • Ultimately these fragments can be engineered and converted to mono- and bi-specific formats that are produced in CHO cells. **María Gonzalez-Pajuelo,** CSO, **FairJourney Biologics** (CONFIRMED) **17:30 Gyrolab technology, a must have in support of biotherapeutic development** • Streamlined and automated immunoassays

		therapeutic efficacy of expanded and activated γδ T cells **Lawrence Lamb,** Executive Vice President, Chief Scientific Officer, **Incysus** (CONFIRMED)		• Applications throughout drug development including bioprocess, PK, ADA • Case study data highlighting the use of the system **Linda Klauss,** Field Application Specialist, **Gyros Protein Technologies** (CONFIRMED)
17:45	Extended Q&A			
17:50	Offsite networking drinks			

Day 2 – Wednesday 16th October 2019				
08:00	Registration opens			
08:50	Conference doors open			
	ROOM MONTREAL **Combination therapies** Chaired by: **Lamine Mbow,** Senior Vice President and Head, **Glenmark Pharma** (CONFIRMED)			
09:00	**Combination immunotherapies to maximise efficacy** • Immunotherapy/immuno-Oncology (IO) is a rapidly expanding class of drugs which has created a paradigm shift in the treatment of some cancers. • Progress in understanding the molecular and cellular determinants of response is providing a framework on which patients will benefit from IO therapy and continues to evolve. • My talk will focus on how best to modulate an anti-cancer immune response through rational/data driven IO combinations **Jim Eyles,** Principal Scientist, **AstraZeneca** (CONFIRMED)			
09:20	**Engineering bispecific antibodies for combination cancer immunotherapy** • Overview of the application of antibody engineering technologies to generate engineered antibodies for combination cancer immunotherapy • T cell bispecific antibodies and tumor-targeted 4-1BB agonists • Off-the-shelf alternatives to CAR-T cells **Christian Klein,** Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich, Roche Pharma Research and Early Development** (CONFIRMED)			
09:40	**Enhancing patient responses with autologous cancer stem cell vaccine in combination with checkpoint inhibitors** • Targeting the cancer stem cell • Soluble PD-1 as a prognostic and predictive biomarker of efficacy • Improving outcomes with this combination treatment **Hans S. Keirstead**, Chief Executive Officer, **AIVITA Biomedical, Inc.** (CONFIRMED)			
10:00	**Panel: Combination therapy strategies** Chaired by: **Lamine Mbow,** Senior Vice President and Head, **Glenmark Pharma** (CONFIRMED) **Christian Klein,** Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich, Roche Pharma Research and Early Development** (CONFIRMED) **Partha Chowdhury,** Senior Director, Head of Antibody Discovery, **Sanofi Genzyme** (CONFIRMED) **Hans S. Keirstead**, Chief Executive Officer, **AIVITA Biomedical, Inc.** (CONFIRMED) **Jim Eyles,** Principal Scientist, **AstraZeneca**			
10:30	Networking break			
	ROOM SINGAPORE **Immune checkpoint modulation** Chaired by: **Igor D'Angelo,** Therapeutic Discovery, Molecular Engineering, **Amgen** (CONFIRMED)	**ROOM HELVETIA 3-5** **Cell therapy** Chaired by: **Hanspeter Gerber,** SVP & CSO, **3T Biosciences** (CONFIRMED)	**ROOM HELVETIA 7** **Combination therapies** Chaired by: **Christian Klein,** Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Centre Zurich, Roche Pharma Research and Early Development** (CONFIRMED)	**ROOM RIO** **Technology showcase** Chaired by: **Ulf Grawunder,** Chief Executive Officer, **NBE therapeutics** (CONFIRMED)

11:25	**CB307: A novel CD137 (4-1BB) agonist Humabody therapeutic for PSMA-positive tumours** • Crescendo Biologics has initiated pre-clinical development of CB307, a novel bispecific Humabody VH targeting CD137 (4-1BB) and prostate specific membrane antigen (PSMA) • The talk will describe the identification, mechanism of action and preclinical characterisation of CB307 • The benefits of using the modular Humabody VH platform, rather than an IgG format to develop this molecule will be discussed, including optimal (monovalent) engagement of both targets with small VH domains and the avoidance of Fc receptor interactions • The unique design of CB307 enables highly potent and tumour selective T-cell co-stimulation **Carolyn Edwards,** Principal Scientist, **Crescendo Biologics** (CONFIRMED)	**The importance of finding cleaner targets for solid tumours** • Conventional cell surface antigens with high expression across tumours are commonly expressed on normal tissues, creating potential for on-target, off-tumour toxicities when targeted by high-potency oncology compounds. • Recent clinical trial data from patients with solid tumours that were treated with immune checkpoint inhibitors demonstrate that CD8+ T cells can mediate deep and durable responses in solid tumours. • How to identify TCRs and pMHC targets involved in mediating complete responses following ICI treatment ? • The most promising approaches to identify pMHC targets and their corresponding TCRs will be discussed **Hanspeter Gerber,** SVP & CSO, **3T Biosciences** (CONFIRMED)	**Immunotherapy combination: how can preclinical models guide the selection of the best combo partner** • Preclinical mouse models are key tools to evaluate the activity of cancer immunotherapies. They are instrumental to understand the mechanism of action of tested compounds, and help identifying rationale combination partners for best anti-tumour efficacy • Here we show how the Pharmacology Group at the Roche Innovation Centre Zurich has been developing over the past years a cutting-edge mouse models platform for in vivo profiling of immunotherapies and their combinations • The translational relevance of the preclinical data obtained will be shown **Sara Colombetti,** Global Head of Oncology Discovery Pharmacology, **Roche Innovation Centre Zurich** (CONFIRMED)	**MoGRAA® discovery engine to generate the functional therapeutic mAbs targeting GPCRs with a unique single cell analysis technique** • GPCR • Monoclonal antibody • Single cell technology **Kiyoshi Takayama,** Founder and President, **NB Health Laboratory Co** (CONFIRMED)
11:45	**Affimer therapeutics as check-point antagonists, demonstration of preclinical efficacy in mice of PD-L1 blockade in combination with a small molecule inducer of pyroptosis** • An introduction to the human Affimer scaffold as a therapeutic platform for the generation of potent antagonists of check point inhibitors such as PD-L1 and LAG-3. • Demonstration of how Affimers proteins can be formatted into several novel formats to generate multi-specifics. • Preclinical validation in mice of an Affimer antagonist to PD-L1, either as monotherapy or in combination with a small molecule inducer of pyroptosis.	**Adoptive TCR-T based immunotherapies using endogenous, engineered, autologous or allogeneic approaches** • Immatics utilizes a proprietary tumor antigen targets discovery platform, XPRESIDENT® which identifies tumor targets and screen cognate TCRs for off-target toxicities • IMA101 is an autologous, endogenous, multi-product T cells against a warehouse of targets against various solid cancers currently in phase 1 clinical trial • IMA201, 202, and 203 are individual autologous, TCR engineered T cell products, in various phase 1 trials for various solid cancers • IMA301 is an allogeneic, TCR engineered T cell product, in preclinical	**Local combination therapies** • Limitations of systemically applied checkpoint blockade and cytokine therapies • Delivery options for local therapy • Our approach to modifications for local retention of biologics • Our results in murine tumour models and human explant cultures **Johannes vom Berg,** Group Leader, Institute of Laboratory Animal Science, **University of Zurich** (CONFIRMED)	**Evaluation of the higher order structure at atomic resolution using NMR** • NMR provides a solution to the need for atomic resolution in HOS characterization • NMR can be applied to intact molecules at natural abundance, with acquisition times reasonable for routine analysis • NMR sample preparation is simple, measurement in physiologically relevant solution • NMR is a high precision analytical technique and produces data that is the ideal input for robust statistical tools required for HOS evaluation **Christian Fischer,** Staff Scientist, MRS Application Development, **Bruker Biospin** (CONFIRMED)

	Amrik Basran, Chief Scientific Officer, **Avacta** (CONFIRMED)	development going to a phase 1 trials for various solid cancers **Ali Mohamed,** VP CMC, **Immatics Inc** (CONFIRMED)		
12:05	**HERA-CD40L: A unique hexavalent CD40 agonist for cancer immunotherapy** • Represents a novel class of crosslinking independent TNFR superfamily agonists • Increases pro-inflammatory state of all CD40-expressing cells examined • Induces antigen-specific T cell activity in vivo • Shows single-agent anti-tumor efficacy in vivo • Well tolerated in pilot monkey tox study **Oliver Hill,** Vice President, Molecular Biology, **Apogenix** (CONFIRMED)	**Breaking down the tumour immunosuppressive barrier to enhance immunotherapy** • Immunosuppressive microenvironment • Arginine metabolism • Myeloid Cells • Immunotherapy **Carmela De Santo,** CRUK New Investigator Fellow, **University of Birmingham** (CONFIRMED)	**Discovery and development of antibody combinations for cancer immunotherapy** • Development of novel antibodies and more powerful therapeutic combinations for immunotherapy is an intense area of focus. • Difficult and/or conserved targets, finding antibodies with unique functionality, and generating early PoC are some of the challenges to the development of novel antibody therapeutics. • Symphogen's approach to discovery and development of potent antibody combinations for cancer immunotherapy, including examples from our clinical pipeline, will be presented. **Johan Lantto,** Project Director, Immuno-Oncology, **Symphogen** (CONFIRMED)	**Fermentation-independent manufacturing of biologics** • Scalable, recombinant cell-free system for discovery and manufacturing • Production of an engineered vaccine • Host-free biosynthesis of challenging biosimilars **Michael Humbert,** Co-Founder & Laboratory Director, **NTxBio** (CONFIRMED)
12:25	Title TBA **Martine Boks,** Scientist, **Merus** (CONFIRMED)	**T4 CAR T cell immunotherapy of patients with refractory head and neck cancer** • A CAR has been engineered using a promiscuous ligand that engages 8 • distinct ErbB dimer species. • Phase 1 evaluation has been initiated in patients with head and neck cancer • using intra-tumoral delivery and phased dose escalation to mitigate risk. • Thirteen patients have been safely treated to date, at doses of up to 1Bn cells, without DLTs and with an efficacy signal evident. **Caroline Hull,** Research Associate, **Kings College London** (CONFIRMED)		**Affinity maturation and optimisation of trastuzumab using RAMP** • We have developed a Rational Affinity Maturation Platform (RAMP) by creating a small library of variants of a given antibody sequence with a relatively high proportion of variants having increased affinity, contrasting existing technologies • We have demonstrated the success of this platform with Cathepsin S antibody (Fsn0503h) and have generated a small library of 66 variants. After one round of RAMP, 50% of the 66 variants have shown increased affinity and some have a 10-fold increase • This is a significant improvement to existing technologies such as phage

				display where maybe 1 in 100 million variants have increased affinity **Anthony O'Kane,** Head of Antibody Discovery, **Fusion Antibodies** (CONFIRMED)
12:45	**Semaphorin 4A as immune checkpoint and regulator of inflammation in allergic asthma** • Novel immune checkpoint • Suppresses experimental allergic asthma • Regulates several arms of immune response • Potentiates Treg cell stability • Modified protein for asthma immunotherapy **Svetlana Chapoval**, Assistant Professor, **University of Maryland** (CONFIRMED)	**Defining manufacturing controls in T cell bioprocessing** • ODE modelling approach to control T cells bio process • Mechanistic T cell model allows prediction of variability in process outcomes with respect to input variability including cell seeding density, dilution rate and frequency and Glucose concentration • Defining first and secondary limiting factors in T cells growth and exhaustion and their effect on the sub-set phenotype • Process optimisation and reduce the risk in T cell bioprocessing **Maryam Shariatzadeh,** Post-Doctoral Researcher, Centre for Biological Engineering, **Loughborough University** (CONFIRMED)		Title TBA **Kader Thiam,** Vice President of Transgenic Technologies, g**enOway** (CONFIRMED)
13:05	Networking lunch			
	ROOM SINGAPORE **Immune checkpoint modulation** Chaired by: **Igor D'Angelo,** Therapeutic Discovery, Molecular Engineering, **Amgen** (CONFIRMED)	**ROOM HELVETIA 3-5** **Manufacture and bioprocessing** Chaired by: **Alan Smith,** Executive Vice President, Technical Operations, **Bellicum** (CONFIRMED)	**ROOM HELVETIA 7** **Biomarkers and precision medicine** Chaired by: **Philip Beer,** Visiting Scientist, **Sanger Institute,** Consultant Genomicist, **NHS** (CONFIRMED)	
14:35	**Targeting evolutionary conserved epitopes of key checkpoint for rational immunotherapy combinations** • Rational approaches to identifying and prioritizing the promising single and combinational immunotherapies should start from the fundamental understanding of the mechanism of actions (MOAs) by the therapeutic intervention of the intact immune system to suppress tumours. • Targeting the conserved epitopes across different species offers a logical approach to preserving the translational fidelity of MOAs by bridging the gap between preclinical and clinical studies. • We will present our Dynamic Precision Library Platform that enables the generation of antagonist and agonist	**Cell therapy supply chain management, logistics and scale out** • Shipper suitability, features and options • Maintaining chain of custody for starting material and product • Logistics reliability and options • Supply chain sustainability and scale-out **Alan Smith,** Executive Vice President, Technical Operations, **Bellicum** (CONFIRMED)	**Quantifying the immune status for precision medicine applications** • HLA-antigen-T cell interactions are at the center of adaptive immunity • From antigens to diseases, what the immune status can tell on immunotherapy • Implementing precision medicine strategies for patient selection and stratification **Tim Fugmann,** Senior Scientific Advisor, **Alithea Bio** (CONFIRMED)	

	antibodies with well-defined attributes by targeting the conserved epitopes of the key check points across different species. We will highlight in vitro and in vivo efficacy and safety data in mono- and combinatorial therapies, together with data associated with their MOAs. • Our unique approach to targeting evolutionarily conserved functional epitopes across different species would serve as a new paradigm toward rational development of single and combinational immunotherapies. **Peter Luo,** Founder and CEO, **Adagene** (CONFIRMED)		
14:55	**Peptides as alternative immune checkpoint inhibitors** • Random Peptide microarrays • Peptide Phage display • Peptides in B7-1/CTLA-4 interaction **Andrei Chapoval,** Director, Russian-American Anti-Cancer Centre, **Altai State University** (CONFIRMED)	**Developing low risk manufacturing processes for cell-based therapies** • Challenges of manufacture process control or cell therapies • Process Case studies • Examples of novel methodological approaches that can deliver lower risk processes in constrained development times **Robert Thomas,** Professor, Manufacturing for Cell and Gene Therapies, Centre for Biological Engineering, **Loughborough University** (CONFIRMED)	**Precision medicine and neuroimmunology – examples of emerging biomarkers** • Neuroimmunology, neuroinflammation, neurodegeneration – setting the stage • Biomarkers, predictors, responders – discussing state of the art • Stratified, individualized, personalized – providing an outlook **Thomas Hach,** Worldwide Brand Medical Director, Neuroscience, **Novartis** (CONFIRMED)
15:15	**A novel Treg subset involved in melanoma immune evasion** • Lymphocytes are particularly rich in FKBP51 (FKBP5gene), an immunophilin better known as the intracellular receptor for FK506 and rapamycin. Melanoma/immune-cell interaction, through PD-L1/PD1, generates FKBP5 splicing, producing a lower molecular weight FKBP51 form, termed FKBP51s • Tregs is a heterogeneous population with respect to their immunosuppressive capability, which is usually increased in melanoma patients. FKBP51s is associated with a highly metabolically active profile of Tregs with strong suppressive capability • Melanoma patients that benefit from immune-checkpoint targeted therapy are recognizable by an expansion of FKBP51s+Treg subset which may be involved in de-activation of stimulatory co-signalling pathways, in support of tumour immune evasion	**Augmenting Analytics using Fluorescent Nanosensors** • For the true potential of Cell and gene therapies (CGTs) to be realised, advancements must be made to optimising their manufacture, such that their production is precise, reproducible and robust • This includes monitoring and control of complex cell culture conditions, such as extracellular and subcellular biochemical parameters, for which there are no readily available automated analytical systems • Biosensors, such as fluorescent nanosensors, provide a tangible solution to augment CGT manufacture, as they enable off-line, online and inline monitoring of the cellular microenvironments that could permit real-time realignment of critical sub-cellular biochemical parameters to enhance CGT manufacture **Veeren Chauhan,** Future Targeted Healthcare Manufacturing Research Fellow, **Nottingham University** (CONFIRMED)	**Mainstreaming of complex genomic analysis in routine oncology practice** • Cancer genomics has the potential to accelerate drug discovery and protect patients from ineffective therapies • Current approaches are inefficient due to suboptimal assay design and restricted access to testing • Closing the loop through the collection of clinical outcome data is essential to unlock the full potential of genomic profiling **Philip Beer,** Visiting Scientist, **Sanger Institute,** Consultant Genomicist, **NHS** (CONFIRMED)

	Fiammetta Romano, Associate Professor of Biochemistry, **University of Naples "Federico II"** (CONFIRMED)		
15:35	**Activating neutrophils by targeting the innate checkpoint CD47/SIRPa** • Neutrophils can be activated to kill tumor cells with IgA • Targeting CD47 or SIRP can greatly enhance the action of neutrophils • Proof of principle with lymphoma and neuroblastoma as targets **Jeanette Leusen,** Associate Professor, Head Immunotherapy group and UMAB, Laboratory of Translational Immunology (LTI), **University Medical Center Utrecht** (CONFIRMED)	**Process development and manufacturing strategies for ATMPs** • Process development of human T-cells for CAR-T immunotherapy manufacture using an automated bioreactor platform • Control of raw materials significantly reduces variation and improves process consistency, resulting in fewer batch failures and reduction in overall process cost • Development of an automated manufacturing facility for the scalable production of human stem cells and T-cells for immunotherapy applications **Elena Costariol,** EngD Researcher, **University College London** (CONFIRMED)	**ROOM HELVETIA 7** **Immunotherapy for non-oncology** Chaired by: **Christopher Barnum,** Director of Neuroscience, **INmune Bio** (CONFIRMED) **Presentation title: IL-21 as a new target for immunosuppressive therapies** • Biology of IL-21 • The role of IL21 in allograft rejection • IL-21 targeted immunotherapy **Carla C. Baan,** Head of Laboratory, Internal Medicine – Transplantation & Nephrology, **Erasmus MC** (CONFIRMED)
15:55	Networking break		
	ROOM HELVETIA 3-5 **Immunotherapy for solid tumours** Chaired by: **Eva Dahlen,** Senior Director, Business Development, **Alligator Bioscience** (CONFIRMED)	**ROOM HELVETIA 7** **Immunotherapy for non-oncology** Chaired by: **Christopher Barnum,** Director of Neuroscience, **INmune Bio** (CONFIRMED)	
16:40	**Re-focusing IL-2 to fuel anti-cancer immunity** • Rationale for the refocusing of IL-2 to promote proliferation of effector cells • Generation of development candidates • In vitro and in vivo studies **Andreas Katopodis,** CEO, **Anaveon** (CONFIRMED)	**Approaching Alzheimer's disease as an immunological disease: role of biomarkers** • Innate immune dysregulation causes chronic inflammation and development of Alzheimer's disease • Approaching AD as an immunologic disease changes the clinical strategy in many ways but perhaps none more important than access to biomarkers • We have developed a suite of biomarkers (both invasive and non-invasive) that extent beyond classical blood inflammatory measures to identify the right patients and track target engagement and treatment response **Christopher Barnum,** Director of Neuroscience, **INmune Bio** (CONFIRMED)	
17:00	**Development of 4-1BB agonists designed for safe and efficacious immunotherapy of cancer** • 4-1BB is a co-stimulator receptor promoting anti-tumour immunity by supporting survival and cytotoxicity of T and NK cells • Clinical development of 4-1BB agonists has been hampered by toxicity and efficacy issues. A next generation of 4-1BB agonists is under development, designed to be primarily active in the tumour environment, anticipated to result in favourable efficacy/safety profiles. • Two different 4-1BB agonists will be described, the monospecific 4-1BB antibody ATOR-1017 and the tumour-targeting bispecific antibody ALG.APV-527, targeting the tumour antigen 5T4 **Eva Dahlen,** Senior Director, Business Development, **Alligator Bioscience** (CONFIRMED)	**Targeting IL-33 for the treatment of asthma** • Genetic studies reveal IL-33 pathway associates with asthma risk • IL-33 activates Type-2 inflammatory pathways • Loss of IL-33 ameliorates Type-2 inflammation in murine models of asthma • Anti-ST2 (IL-33 Receptor) is being tested in asthma patients **Rajita Pappu,** Senior Scientist, **Genentech** (CONFIRMED)	

17:20	**Fibroblast activation protein (FAP)-selective delivery of CD40 agonistic DARPin® protein for tumor-localized immune activation** • CD40 receptor, an interesting target for tumor immunotherapy able to activate both innate and adaptive immune system • Development of a bispecific DARPin® protein to activate CD40 locally at the tumor site to reduce toxicity and improve efficacy of cancer immunotherapy • Presenting data demonstrating a FAP-dependent activation of CD40 and subsequent biological response on different immune cell subsets through an innovative CD40 agonist DARPin® protein **Nicolò Rigamonti,** Project Leader and Biology Lead, **Molecular Partners** (CONFIRMED)	**Selective co-stimulation blockade with CD28 antagonist: FR104** • FR104 is a humanized pegylated anti-CD28 Fab fragment • Blocking selectively CD28 while sparing CTLA-4 induces antigen-specific immune regulation and Tregs. • Superiority over CTLA4-Ig in humanized mouse and NHP transplant or chronic inflammatory models. • Clinical phase 1 demonstrated good safety and PK profile (eg: no cytokine release) and dose-dependent inhibition of immune responses in human. **Nicolas Poirier,** Chief Scientific Officer, **OSE ImmunoTherapeutics** (CONFIRMED)
17:40	Poster presentation and networking drinks	

Day 3 – Thursday 17th October 2019		
08:00	Registration opens	
08:50	Conference doors open	
	ROOM SINGAPORE **Keynote plenary – world leading research** Chaired by: **Abhishek Kashyap,** Project Group Leader, Cancer Immunology, Department of Biomedicine, **University Hospital Basel, University of Basel** (invited)	
09:00	Chair's opening remarks	
09:05	**New strategies for boosting anti-tumor immunity: Anti-angiogenic immunotherapy and Antisense oligonucleotide immunotherapeutics.** • The talk will present two new approaches of boosting antitumor immunity: • Combining immunotherapy with anti-angiogenic agents: pre clinical mechanistic and therapeutic insights will be presented on the combination of agonist anti-CD40 mAb and the dual blockade of VEGFA/Angiopoetin-2 • Utilising antisense oligonucleotides (ASO) to target PDL1: first evidence for efficacy in murine tumor models of a new ASO targeting PDL1 will be presented **Abhishek Kashyap,** Project Group Leader, Cancer Immunology, Department of Biomedicine, **University Hospital Basel, University of Basel** (CONFIRMED)	
09:30	**How to individualize immunotherapy** • Human model systems • Understanding response and resistance • Tumour microenvironment • individualized treatment strategies **Dirk Jäger,** Managing Director, **NCT Heidelberg** (CONFIRMED)	
09:55	**MR1T cells: the new players in cell therapy of solid tumours** • Identification of MR1T cells, a novel population of tumour-specific T cells • Characterization of MR1T phenotype and effector functions • Exploitation of Mr1T cell in cell-therapy of solid tumours **Gennaro De Libero,** Professor of Tumour Immunology, **University of Basel** (CONFIRMED)	
10:20	Networking break	
	ROOM SINGAPORE **Immunotherapy for solid tumours** Chaired by: **Paul Cockle,** Head of Immunology, **PsiOxus Therapeutics** (CONFIRMED)	**ROOM RIO** **Therapeutic vaccines and oncolytics** Chaired by: **Eric Halioua,** President and CEO, **PDC*line Pharma** (CONFIRMED)
11:20	**A novel bispecific agonistic antibody designed to increase the tumour neoantigen-specific T cell repertoire** • Alligator has developed a novel concept involving bispecific agonistic antibodies designed to increase the tumour neoantigen-specific T cell repertoire	**Personalized neoantigen plasmid DNA vaccine induces potent CD8-dominated specific T cell responses for cancer treatment** • Vaccibody plasmid DNA vaccine Technology and Mode of Action

	• Preclinical in vitro data and in vivo data using a transgenic mouse model will be presented **Karin Hägerbrand,** Scientist, Immuno-oncology, **Alligator Bioscience** (CONFIRMED)	• Induction of potent CD8+ T cell and tumor protective immune responses in pre-clinical models • Clinical experience in patients with HPV16+ High Grade Cervical Intraepithelial Neoplasia (HSIL, CIN 2/3) • Update from on-going clinical trial (VB N-01) in patients with locally advanced or metastatic solid tumours treated with VB10.NEO in combination with CPI **Karoline Schjetne,** VP Scientific Affairs, **Vaccibody** (CONFIRMED)
11:45	**Allogeneic inflammatory DCs as intratumoral immune primer: starting the engine of the immune system** • Activated DCs, named ilixadencel, mimic virally infected DCs and produce a potent set of chemokines and cytokines when injected intratumorally • Ilixadencel then recruits and activates NK cells and immature DCs from the patient, inducing cross-presentation of neoantigens to CD8+ T cells • Preclinical synergy has been established with checkpoint inhibitors (e.g. PD-1) and immune enhancers (e.g. 4-1BB) • Phase I/II studies have been completed in RCC, HCC and GIST, and Phase II controlled data in RCC is released in Q3 2019 **Sijme Zeilemaker,** Senior Director Business Development, **Immunicum** (CONFIRMED)	**New class of Ag-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line (PDC*line)** • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors • The technology can be applied for any cancer **Eric Halioua,** President and CEO, **PDC*line Pharma** (CONFIRMED)
12:10	**Identification of biomarkers revealing effective immunotherapy at an early stage in the treatment of solid tumors** • Immune checkpoint therapy is shaping the tumor microenvironment by an upregulation and downregulation of specific biomarkers, revealed by the newest advanced single cell technologies (scRNAseq, mass cytometry) • Effective immunotherapy can be unravelled at a systemic level, from the bone marrow through the blood • In a murine model, biomarkers screened at an early stage (three days after start of immunotherapy) can predict the clinical outcome **Guillaume Beyrend**, Marie Curie Early Stage Researcher, **Leiden University Medical Center** (CONFIRMED)	**Immunotherapy and HIV-1 infection: Success of combinatorial therapies** • HIV-1 infected and treated patients who received therapeutic vaccination and I will discuss • current work on how to improve therapeutic vaccination using immune checkpoint inhibitors **Nabila Seddiki,** Associate Professor, **INSERM** (CONFIRMED)
12:35	**T-SIGn: a cancer gene therapy platform for localized combination immunotherapy** • Immune responses are induced and act locally in tissues and draining secondary lymphoid organs. Therefore, engaging the immune system locally should be the best way to induce effective anti-tumour immune responses	**Utilizing a live modified Vaccinia ankara virus to deliver cancer antigens in highly immunogenic forms of virus like particles** • Design of a MUC1 VLP • In vitro characterization of production of hypo glycosylated MUC1 in infected cells

	• The T-SIGn cancer gene therapy platform is designed to produce transgenes that engage the immune system locally within the tumour microenvironment • The viral vector for this platform, the chimeric group B oncolytic adenovirus enadenotucirev, can be dosed systemically to replicate and enable transgene expression selectively within epithelial tumours **Paul Cockle,** Head of Immunology, **PsiOxus Therapeutics** (CONFIRMED)	• Therapeutic Efficacy of MVA-VLP-MUC1 vaccine in Human MUC1 transgenic mice **Farshad Guirakhoo,** Chief Scientific Officer, **GeoVax** (CONFIRMED)
13:00	Networking lunch	
	ROOM SINGAPORE **Closing plenary** **Next generation immunotherapy**	
14:00	**ImmunoSTATs: a novel biologics platform for antigen-specific immunotherapy** • ImmunoSTATs are proprietary biologics that incorporate, in a single molecular framework, key signals needed to selectively modulate • antigen-specific T cells: namely, the pMHC-complex and relevant co-stimulatory/co-inhibitory signals, dependent upon the disease indication. • The lead clinical candidate CUE-101 is comprised of HLA-A*0201, genetically bound to a HPV16 epitope (E7 protein, peptide 11-20), along with affinity-attenuated human interleukin-2 to selectively activate and expand HPV16 E711-20-specific CD8+ T cells for HPV-driven malignancies. **Anish Suri,** Senior Vice President, Chief Scientific Officer, **Cue Biopharma** (CONFIRMED)	
14:20	**Affimer therapeutics: a versatile platform for the generation of novel immunotherapies** • The Affimer platform which is based on the human protease inhibitor, Stefin A, can be used to generate antagonists and agonists to a range of targets which play an important role in cancer • The Affimer binders have been used in a range of applications to generate novel immunotherapies, either as multivalent formats or bispecifics • We have also shown that Affimer therapeutics can be DNA encoded and delivered into cells to hit an intracellular target or be expressed from transformed mouse muscle tissue to give therapeutic levels of Affimer protein in the circulation in vivo **Amrik Basran,** Chief Scientific Officer, **Avacta** (CONFIRMED)	
14:40	**Improving target discovery for solid tumours** • How to address the challenges of finding TCR targets? • How to monitor changes in TCR specificity during TCR engineering? • Best ways to identify endogenous TCRs with optimal anti-tumour activities? • Impact of HLA restriction on patient populations: need for diagnostics? • Will HLA and target downregulation limit the durability of responses? **Luke Lee,** CEO and Founder, **3T Biosciences** (CONFIRMED)	
15:00	Chairman's closing remarks	
15:10	Closing remarks from Terrapinn	

15:15	End of congress – see you in 2020!